Table 2.
Comparison of Clinicopathological Characteristics of No Early-Recurrence and Early-Recurrence Patients
| Parameter | No Early-Recurrence | Early-Recurrence | p-value |
|---|---|---|---|
| (n=250) | (n=53) | ||
| Gender: female/male (n) | 25/225 | 6/47 | 0.773 |
| Age (years) | 52.55±10.95 | 50.69±11.52 | 0.259 |
| HBsAg: negative/positive (n) | 52/198 | 11/42 | 0.994 |
| Family history: absent/present (n) | 217/33 | 47/6 | 0.711 |
| Drinking: absent/present (n) | 126/124 | 31/22 | 0.284 |
| Smoking: absent/present (n) | 133/117 | 29/24 | 0.841 |
| Cirrhosis: absent/present (n) | 20/230 | 8/45 | 0.105 |
| MVI: absent/present (n) | 197/53 | 45/8 | 0.314 |
| WBC (×109/L) | 6.66±2.44 | 6.36±2.37 | 0.418 |
| NEUT (×109/L) | 4.10±2.14 | 3.88±1.72 | 0.485 |
| LYMPH (×109/L) | 1.77±0.63 | 1.59±0.51 | 0.052 |
| Platelets (×109/L) | 180.65±78.37 | 191.91±88.76 | 0.357 |
| Albumin (g/L) | 39.11±5.23 | 40.49±4.42 | 0.075 |
| Globulin (g/L) | 30.67±5.76 | 31.06±5.06 | 0.650 |
| TBIL (μmol/L) | 15.19±13.72 | 13.78±6.23 | 0.507 |
| DBIL (μmol/L) | 5.62±4.42 | 5.05±2.81 | 0.355 |
| ALT (U/L) | 41.28±37.34 | 51.06±49.11 | 0.096 |
| AST (U/L) | 46.54±53.35 | 48.30±44.57 | 0.832 |
| GGT (U/L) | 84.50±66.65 | 107.03±76.50 | 0.030* |
| Tumor size (cm) | 7.38±6.64 | 8.50±4.73 | 0.241 |
| Tumor number: single/multiple (n) | 190/60 | 35/18 | 0.132 |
| Tumor differentiation: I/II/III (n) | 44/94/112 | 5/19/29 | 0.251 |
| BCLC stage: 0/A/B (n) | 18/124/108 | 2/24/27 | 0.443 |
| GLR | 54.66±48.84 | 75.83±58.43 | 0.006* |
Note: *P-value indicates statistically significant.
Abbreviations: n, number of patients; HBsAg, hepatitis B surface antigen; MVI, microvascular invasion; WBC, white blood cell; NEUT, neutrophil count, LYMPH, lymphocyte count; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, Gamma-glutamyl transpeptidase; BCLC, barcelona-clinic liver cancer; GLR, GGT to lymphocyte ratio.